NPPA fixes price of 2 inhaler devices

Inhaler is a combination medicine used to relieve symptoms such as wheezing, shortness of breath, chest tightness, breathing difficulties, coughing, etc. caused by asthma and chronic obstructive pulmonary disease (COPD).

734
NPPA Price of drugs
2 min. read

National Pharmaceutical Pricing Authority (NPPA) has fixed the price of inhaler device Digital Dose Counter under the brand name Digihale manufactured by Glenmark Pharmaceuticals Ltd under the Drugs Price Control Order- 2013 (DPCO 2013). The drug pricing regulator has also fixed price of Synchrobreathe, an Inhaler Device manufactured by Cipla Ltd under DPCO 2013.

For notification, Click here

Inhaler is a combination medicine used to relieve symptoms such as wheezing, shortness of breath, chest tightness, breathing difficulties, coughing, etc. caused by asthma and chronic obstructive pulmonary disease (COPD).

NPPA in its 71st meeting dated December 9, 2019 deliberated upon the applications or representations of Glenmark Pharmaceuticals Ltd and accepted the recommendations of the multidisciplinary committee of experts to give separate price of ‘digital dose counter’ under the brand “Digihaler” for Glenmark Pharmaceuticals Ltd under para 11(3) of DPCO 2013.

NPPA had received an application from Glenmark Pharmaceuticals Ltd for separate price of ‘digital dose counter’ under the brand “Digihaler” for its formulation (a) Budesonide 100mcg+ Formeterol 6mcg per dose Inhaler 120 MDI (b) Budesonide 200mcg+ Formeterol 6mcg per dose Inhaler 120 MDI and (c) Budesonide 400mcg+ Formeterol 6mcg per dose Inhaler 120 MDI having digital dose counter.

Also read another news of NPPA, Click the links below
NPPA fixes retail prices of 75 formulations under DPCO 2013
NPPA fixes retail prices of 12 formulations
NPPA fixes retail prices of 21 formulations

The application of Glenmark Pharmaceuticals Ltd was placed before the multidisciplinary committee of experts in its 14th meeting dated December 4, 2019. Two Pharmacoeconomic experts were co-opted in the Committee.

NPPA had received an application from Cipla Ltd also for separate price of ‘Synchrobreathe Inhaler Device’ for its formulation (a) Budesonide 200mcg+ Formeterol 6mcg per dose Inhaler 120 MDI (b) Budesonide 400mcg+ Formeterol 6mcg per dose Inhaler 120 MDI.

The application of Cipla Limited was placed before the multidisciplinary committee of experts in its 14th meeting dated December 4, 2019. Two Pharmacoeconomic experts were co-opted in the Committee.

The Committee noted that a separate price could be considered to promote incremental innovation. Accordingly, it recommended special price of “Synchrobreathe Inhaler Device” for Cipla Limited under para 11(3) of DPCO 2013.

LEAVE A REPLY

Please enter your comment!
Please enter your name here